PortfoliosLab logoPortfoliosLab logo
PFE vs. OKTA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PFE vs. OKTA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pfizer Inc. (PFE) and Okta, Inc. (OKTA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PFE achieves a 8.79% return, which is significantly lower than OKTA's 34.49% return.


PFE

1D
0.15%
1M
0.96%
YTD
8.79%
6M
4.79%
1Y
12.89%
3Y*
-7.78%
5Y*
-3.35%
10Y*
2.11%

OKTA

1D
-1.03%
1M
48.71%
YTD
34.49%
6M
28.95%
1Y
16.08%
3Y*
15.20%
5Y*
-12.47%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

PFE vs. OKTA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PFE
Pfizer Inc.
8.79%0.65%-2.22%-41.26%-10.41%66.70%3.07%-6.91%24.82%9.25%
OKTA
Okta, Inc.
34.49%9.73%-12.96%32.49%-69.52%-11.83%120.39%80.83%149.12%7.83%

Correlation

The correlation between PFE and OKTA is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.10

Correlation (3Y)
Calculated over the trailing 3-year period

0.11

Correlation (5Y)
Calculated over the trailing 5-year period

0.09

Correlation (All Time)
Calculated using the full available price history since Apr 7, 2017

0.12

Fundamentals

Market Cap

PFE:

$150.21B

OKTA:

$20.66B

EPS

PFE:

$1.31

OKTA:

$0.96

PE Ratio

PFE:

19.98

OKTA:

120.69

PEG Ratio

PFE:

0.36

OKTA:

0.18

PS Ratio

PFE:

2.36

OKTA:

9.36

PB Ratio

PFE:

1.67

OKTA:

3.00K

Total Revenue (TTM)

PFE:

$63.32B

OKTA:

$2.23B

Gross Profit (TTM)

PFE:

$43.91B

OKTA:

$1.73B

EBITDA (TTM)

PFE:

$16.94B

OKTA:

$235.06M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PFE vs. OKTA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE
PFE Risk / Return Rank: 6060
Overall Rank
PFE Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
PFE Sortino Ratio Rank: 5656
Sortino Ratio Rank
PFE Omega Ratio Rank: 5454
Omega Ratio Rank
PFE Calmar Ratio Rank: 6666
Calmar Ratio Rank
PFE Martin Ratio Rank: 6464
Martin Ratio Rank

OKTA
OKTA Risk / Return Rank: 5454
Overall Rank
OKTA Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
OKTA Sortino Ratio Rank: 5454
Sortino Ratio Rank
OKTA Omega Ratio Rank: 5353
Omega Ratio Rank
OKTA Calmar Ratio Rank: 5353
Calmar Ratio Rank
OKTA Martin Ratio Rank: 5555
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PFE vs. OKTA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Okta, Inc. (OKTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PFEOKTADifference
Sharpe ratioReturn per unit of total volatility

+0.25

Sortino ratioReturn per unit of downside risk

+0.09

Omega ratioGain probability vs. loss probability

1.12

1.11

0.00

Calmar ratioReturn relative to maximum drawdown

1.13

0.43

+0.70

Martin ratioReturn relative to average drawdown

2.27

1.02

+1.26

PFE vs. OKTA - Sharpe Ratio Comparison

The current PFE Sharpe Ratio is 0.54, which is higher than the OKTA Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of PFE and OKTA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PFE vs. OKTA - Drawdown Comparison

The maximum PFE drawdown since its inception was -69.24%, smaller than the maximum OKTA drawdown of -84.57%. Use the drawdown chart below to compare losses from any high point for PFE and OKTA.


Loading charts...

Drawdown Indicators


PFEOKTADifference

Max Drawdown

Largest peak-to-trough decline

-69.24%

-84.57%

+15.33%

Max Drawdown (1Y)

Largest decline over 1 year

-11.47%

-37.75%

+26.28%

Max Drawdown (3Y)

Largest decline over 3 years

-40.43%

-50.57%

+10.14%

Max Drawdown (5Y)

Largest decline over 5 years

-58.96%

-83.43%

+24.47%

Max Drawdown (10Y)

Largest decline over 10 years

-58.96%

Current Drawdown

Current decline from peak

-45.68%

-60.14%

+14.46%

Average Drawdown

Average peak-to-trough decline

-22.90%

-38.27%

+15.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.70%

15.82%

-10.12%

Volatility

PFE vs. OKTA - Volatility Comparison

The current volatility for Pfizer Inc. (PFE) is 5.07%, while Okta, Inc. (OKTA) has a volatility of 32.92%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than OKTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PFEOKTADifference

Volatility (1M)

Calculated over the trailing 1-month period

5.07%

32.92%

-27.85%

Volatility (6M)

Calculated over the trailing 6-month period

14.62%

48.12%

-33.50%

Volatility (1Y)

Calculated over the trailing 1-year period

23.84%

54.65%

-30.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.48%

57.50%

-32.02%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.89%

53.99%

-30.10%

Dividends

PFE vs. OKTA - Dividend Comparison

PFE's dividend yield for the trailing twelve months is around 6.56%, while OKTA has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
OKTA
Okta, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
6.56%6.91%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.53%3.69%3.47%

Financials

PFE vs. OKTA - Financials Comparison

This section allows you to compare key financial metrics between Pfizer Inc. and Okta, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B25.00B20222023202420252026
14.45B
765.00K
(PFE) Total Revenue
(OKTA) Total Revenue
Values in USD except per share items

PFE vs. OKTA - Profitability Comparison

The chart below illustrates the profitability comparison between Pfizer Inc. and Okta, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%80.0%20222023202420252026
67.3%
77.8%
Portfolio components
PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.

OKTA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Okta, Inc. reported a gross profit of 595.00K and revenue of 765.00K. Therefore, the gross margin over that period was 77.8%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.

OKTA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Okta, Inc. reported an operating income of 56.00K and revenue of 765.00K, resulting in an operating margin of 7.3%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.

OKTA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Okta, Inc. reported a net income of 74.00K and revenue of 765.00K, resulting in a net margin of 9.7%.


Frequently Asked Questions


PFE and OKTA have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

OKTA has higher volatility (32.92%) compared to PFE (5.07%). In terms of maximum drawdown, PFE dropped -69.24% vs OKTA's -84.57%.

PFE currently has the higher Sharpe Ratio (0.54 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PFE and OKTA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer